Bortezomib
- Catalog NO.:A18332
- CAS No. : 179324-69-7
- Molecular Formula:C19H25BN4O4
- Molecular Weight: 384.24
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 179324-69-7 | Appearance | Light yellow powder |
Catalog Number | A18332 | MDL Number | MFCD09056737 |
Molecular Formula | C19H25BN4O4 | Molecular Weight | 384.24 |
Boiling Point | Melting Point | 123oC | |
Flash Point | Density | 1.214 | |
Synonyms | ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Danger | UN Number | UN3249 |
Hazard Statements | H300; H310; H330; H372 | Class | 6.1 |
Precautionary Statements | P260; P284; P301+P310; P304+P340; P320; P330; P361; P302+P350; P405; P501 | Packing Group | II |
Description
Bortezomib is a dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy. |